The ALINA study is a randomized controlled phase III study evaluating the use of adjuvant alectinib compared to platinum-based chemotherapy in stage IB–IIIA ALK-positive NSCLC who have received complete resection. The gene discussed is ALK; the disease is non-small cell lung carcinoma.